等待开盘 04-03 09:30:00 美东时间
+0.080
+7.34%
Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 47.31 percent increase over losses of $(0.26) per share from the same period last year. The company
03-12 04:09
Companies Reporting Before The Bell • Sprinklr (NYSE:CXM) is estimated to repor...
03-11 19:11
Elutia (NASDAQ:ELUT) is gearing up to announce its quarterly earnings on Wednes...
03-11 02:01
Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid
03-04 21:07
Gainers Athira Pharma (NASDAQ:ATHA) stock rose 70.0% to $7.03 during Thursday'...
2025-12-19 01:06
Elutia Inc. announced it will release its third quarter 2025 financial results after market close on November 6, 2025. A conference call and webcast will be held on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. Registration is required to access the dial-in number and personalized PIN. A live and archived webcast will be available on the Elutia website. For more information, visit the "Investors" section at investors.elutia.com...
2025-10-23 20:05
Elutia Inc.'s CEO, Dr. Randy Mills, will present at the LD Micro Main Event XIX in San Diego on October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET). The presentation will be available via live webcast. Elutia management will also hold 1x1 investor meetings. Interested investors can contact an LD Micro representative or email IR@elutia.com. Elutia specializes in drug-eluting biomatrix technologies aimed at improving compatibility between medical devi...
2025-10-14 20:05
Elutia Inc. appoints Guido J. Neels to its Board of Directors, bringing over 40 years of medical technology leadership experience. Neels, an Operating Partner at EW Healthcare Partners, will also join the audit committee. The company thanks W. Matthew Zuga and Maybelle Jordan for their service as they step down. Neels' expertise is expected to support Elutia's strategic transformation and innovation in drug-eluting biomatrix technology for breast...
2025-10-10 12:00
Elutia Inc. sold its BioEnvelope business to Boston Scientific for $88 million and plans to use the proceeds to develop and launch NXT-41x, a biomatrix targeting mastectomy reconstruction infections. The product aims to reduce complications in breast reconstruction, a $1.5 billion U.S. market. Elutia expects to bring NXT-41x to market by mid-2027.
2025-10-01 12:41
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management -GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Elutia Inc.
2025-09-16 20:17